Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term BREAST-CANCER. Found 30 abstracts

no pagination
Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D, Nccn. Survivorship: Pain Version 1.2014 Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2014 Apr;12(4):488-500.   PMCID: No NIH funds
Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. American journal of hematology. 2014 Jun;89(6):639-45.   PMCID: 4137041
Hakanson M, Cukierman E, Charnley M. Miniaturized pre-clinical cancer models as research and diagnostic tools. Advanced Drug Delivery Reviews. 2014 Apr;69:52-66.   PMCID: PMC4019677
Manne S, Kashy D, Albrecht T, Wong YN, Flamm AL, Benson AB, Miller SM, Fleisher L, Buzaglo J, Roach N, Katz M, Ross E, Collins M, Poole D, Raivitch S, Miller DM, Kinzy TG, Liu T, Meropol NJ. Knowledge, Attitudes, and Self-efficacy as Predictors of Preparedness for Oncology Clinical Trials: A Mediational Model. Medical Decision Making. 2014 May;34(4):454-63.   PMCID: PMC3991731
Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural History, Growth Kinetics, and Outcomes of Untreated Clinically Localized Renal Tumors Under Active Surveillance. Cancer. 2009 Jul;115(13):2844-52.   PMCID: PMC2860784
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets. 2009 Mar;13(3):339-62.   PMCID: PMC2670612
Huo DZ, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, Hope K, Olopade OI. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. Journal of Clinical Oncology. 2009 Mar;27(8):1184-90.   PMCID: PMC2667822
Jenkins S, Raghuraman N, Eltoum I, Carpenter M, Russo J, Lamartiniere CA. Oral Exposure to Bisphenol A Increases Dimethylbenzanthracene-Induced Mammary Cancer in Rats. Environmental Health Perspectives. 2009 Jun;117(6):910-5.   PMCID: PMC2702405
Putt M, Long JA, Montagnet C, Silber JH, Chang VW, Liao KJ, Schwartz JS, Pollack CE, Wong YN, Armstrong K. Racial Differences in the Impact of Comorbidities on Survival Among Elderly Men With Prostate Cancer. Medical Care Research and Review. 2009 Aug;66(4):409-35.   PMCID: PMC2780425
Wang C, O'Neill SM, Rothrock N, Gramling R, Sen A, Acheson LS, Rubinstein WS, Nease DE, Ruffin MI, F HITr Grp. Comparison of risk perceptions and beliefs across common chronic diseases. Preventive Medicine. 2009 Feb;48(2):197-202.   PMCID: PMC 2720609
Williams SJ, Cvetkovic D, Hamilton TC. Vitamin A metabolism is impaired in human ovarian cancer. Gynecologic Oncology. 2009 Mar;112(3):637-45.   PMCID: PMC 2737361
Huang QH, Gumireddy K, Schrier M, Le Sage C, Nagel R, Nair S, Egan DA, Li AP, Huang GH, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E, Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biology. 2008 Feb;10(2):202-U83.
Lu ML, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, Cryns VL. Aspirin sensitizes cancer cells to TRAIL-Induced apoptosis by reducing surviving levels. Clinical Cancer Research. 2008 May;14(10):3168-76.
Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, Garden AS, Spencer SA, Jones C, Movsas B. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: A radiation therapy oncology group analysis. International Journal of Radiation Oncology Biology Physics. 2008 Feb;70(2):353-60.
Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2007 Nov;107(2):260-5.
Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, Dargemont C, Garcia de Herreros A, Bellacosa A, Larue L. Activation of NF-kappa B by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. 2007 Nov;26(53):7445-56.
Manne SL, Chung DC, Weinberg DS, Vig HS, Catts Z, Cabral MK, Shannon K, Meropol NJ. Knowledge and attitudes about Microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. Cancer Epidemiology Biomarkers & Prevention. 2007 Oct;16(10):2110-7.
Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 2007 Dec;357(25):2552-61.
Torres-Roca JF, DeSilvio M, Mora LB, Khor LY, Hammond E, Ahmad N, Jove R, Forman J, Lee RJ, Sandier H, Pollack A. Activated STAT3 as a correlate of distant metastasis in prostate cancer: A secondary analysis of radiation therapy oncology group 86-10. Urology. 2007 Mar;69(3):505-9.
Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncology. 2007 Jul;8(7):613-24.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term BREAST-CANCER

BREAST-CANCER CHEMOTHERAPY SURVIVAL PROSTATE-CANCER EXPRESSION RADIOTHERAPY HEALTH BELIEF MODEL SUSCEPTIBILITY RANDOMIZED CONTROLLED-TRIAL RISK Cancer FAMILY-HISTORY IN-VIVO GROWTH WOMEN cancer OVARIAN-CANCER CELL LUNG-CANCER HEALTH ADHESION MOLECULES PSYCHOLOGICAL IMPACT Extracellular matrix SPONTANEOUS GENE-EXPRESSION control social epidemiology RECEPTOR COACTIVATOR AIB1 ETHNIC WORRY ASSOCIATION POSTHERPETIC NEURALGIA cetuximab MEDIATED APOPTOSIS ABC transporter PERIPHERAL NEUROPATHY NEUROPATHIC PAIN TUMORICIDAL ACTIVITY PHASE-II ALCOHOL disparities FUNCTIONAL ASSESSMENT culturing devices E-cadherin DISABILITY E-CADHERIN EXPRESSION Zeb METASTATIC PERCEPTIONS GENE-REGULATION AGE CARRIER PROBABILITIES NONSTEROIDAL ANTIINFLAMMATORY DRUGS Ottawa Decision Support Framework MONOCLONAL-ANTIBODY E-CADHERIN BMI body weight CARBOPLATIN Cancer models POPULATION comorbidity GERMLINE MUTATIONS OF-THE-LITERATURE Vitamin A RACIAL MICE PHYSICAL-ACTIVITY LYNCH-SYNDROME administrative data GROUP RTOG SQUAMOUS-CELL CARCINOMAS LIGAND-INDUCED APOPTOSIS MESSENGER-RNA Microfabricated model systems PREVALENCE PROGRESSION ovarian cancer BEHAVIORS TRANSCRIPTION-3 Cellular retinol binding protein 1 TAMOXIFEN RESISTANCE SMAD-INTERACTING PROTEIN-1 SELF-EFFICACY ESTROGEN MEDIATED DRUG-RESISTANCE Oncology PARTICIPATION CD44S EXPRESSION Worry CANCER-SUSCEPTIBILITY GENES Perceived UNREALISTIC OPTIMISM VALIDITY Family history TUMORS SURFACE EPITHELIAL-CELLS Medical Informatics OBESITY NETWORK Microfluidics bisphenol A apoptosis-mammary cancer-proliferation-steroid receptor coactivators head and neck cancer POSTMENOPAUSAL MANAGEMENT GLAND DEVELOPMENT PERINATAL EXPOSURE ACUTE MYELOID-LEUKEMIA BLACK POSTMENOPAUSAL WOMEN Pre-clinical drug assessment Cell adhesion-mediated drug resistance slug TUMOR HUMAN-PAPILLOMAVIRUS YOUNG-WOMEN OVERWEIGHT BRANCHING MORPHOGENESIS TUMOR-SUPPRESSOR GENE PHASE-III TRIAL TYROSINE KINASE INHIBITORS Perceived severity TOXICITY Attitudes Perceived risk survival analysis CELL-BASED ASSAYS CHOP METASTATIC COLORECTAL-CANCER patients cancer clinical trials Diabetes PROTEIN-INTERACTION PACLITAXEL DECISIONAL CONFLICT erlotinib PROGNOSIS SMOKING EXTRACELLULAR-MATRIX INDIVIDUALS chemotherapy resistance STAGE health-related quality of life ADVANCED HEAD MODEL RECEPTOR-INDUCED APOPTOSIS Medicare P53 NETWORK OPIOID ASSESSMENT CELL CARCINOMA
Last updated on Friday, December 06, 2019